

INNOVATIVE AS WELL AS AFFORDABLE MOLECULAR DIAGNOSTIC SOLUTIONS

February 14, 2019



Suraksha Diagnostic Pvt. Ltd (SDPL), a centre of innovation, is today one of the trusted names in the healthcare industry with its unmatched international standards. The only Lab in Eastern India with the prestigious CAP(College of American Pathology) accreditation. It is known for pioneering the introduction of latest technologies as well as leading the academic challenge by setting up the only R&D facilities for Clinical work in the field of Genomics. Serving for almost three decades through its 41 centres all over the country is now proud to possess almost every possible diagnostic technology. The only Pathological Lab in Eastern India to have a NGS, LC-MS/MS, FISH, ICP capabilities, with more than 4000 tests enlisted in the scope.

Suraksha now partners with Clugenix a San Francisco based biotech company, led by Dr. Joydeep Mukherjee (a globally recognized, multiple award-winning researcher in oncology and infectious diseases genomics in Toronto and UCSF) focused on making translational genomics technologies accessible globally to the Indian population. Clugenix will make available to Suraksha the latest developments in Molecular Biology. More importantly together they will work to set up the protocols for the Indian population in genomics. A lot of this research being done in house, will help to reduce the cost of these expensive tests considerably. Together we will be launching to design the Next Gen Sequencing panel for Breast Cancer for Indian women as our first Research Project out of this JV. This initiative once again confirms Suraksha's commitment to accelerate the deployment of highly innovative as well as affordable molecular diagnostic solutions to India's patient population.